Matthew P Cheng1, Claire Nour Abou Chakra2, Cedric P Yansouni1, Sonya Cnossen2, Ian Shrier2, Dick Menzies3, Christina Greenaway2,4. 1. Division of Infectious Diseases and Department of Medical Microbiology, McGill University Health Centre, Montreal, Quebec, Canada. 2. Centre for Clinical Epidemiology, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada. 3. Respiratory Epidemiology Unit, McGill University Health Centre, Montreal, Quebec, Canada. 4. Division of Infectious Diseases, Jewish General Hospital, McGill University, Montreal, Quebec, Canada.
Abstract
Background: Cancer is a known risk factor for developing active tuberculosis (TB). We determined the incidence and relative risk of active TB in cancer patients compared to the general population. Methods: Electronic databases were searched up to December 2015: Medline, Medline InProcess, EMBASE, PubMed, the Cochrane Database of Systematic Reviews, Cancerlit, and Web of Science. Studies of pathologically confirmed cancer patients were included if active TB was identified concurrently or after the diagnosis. Cumulative incidence rate/100,000 population (CIR) of new cases of TB occurring in cancer patients and comparative incidence rate ratios (IRR) to the general population from the same country of origin were estimated. A random effect meta-analysis was conducted on the CIR and IRR. Results: A total of 23 studies reporting 593 TB cases occurring in 324,041 cancer patients between 1950 and 2011 were identified. In a meta-analysis of 6 studies conducted in the US in 317,243 cancer patients (98% of all patients) the CIR of active TB decreased by 3 fold and 6.5 fold in hematologic and solid cancers respectively before and after 1980. After 1980 the CIR of active TB was highest in hematologic (219/100,000 population, IRR=26), head and neck (143; 16), lung cancers (83; 9) and was lowest in breast and other solid cancers (38; 4). Conclusions: Individuals living in the US with hematologic, head and neck, and lung cancers had a 9-fold higher rate of developing active TB compared to those without cancer and would benefit from targeted latent TB screening and therapy.
Background: Cancer is a known risk factor for developing active tuberculosis (TB). We determined the incidence and relative risk of active TB in cancerpatients compared to the general population. Methods: Electronic databases were searched up to December 2015: Medline, Medline InProcess, EMBASE, PubMed, the Cochrane Database of Systematic Reviews, Cancerlit, and Web of Science. Studies of pathologically confirmed cancerpatients were included if active TB was identified concurrently or after the diagnosis. Cumulative incidence rate/100,000 population (CIR) of new cases of TB occurring in cancerpatients and comparative incidence rate ratios (IRR) to the general population from the same country of origin were estimated. A random effect meta-analysis was conducted on the CIR and IRR. Results: A total of 23 studies reporting 593 TB cases occurring in 324,041 cancerpatients between 1950 and 2011 were identified. In a meta-analysis of 6 studies conducted in the US in 317,243 cancerpatients (98% of all patients) the CIR of active TB decreased by 3 fold and 6.5 fold in hematologic and solid cancers respectively before and after 1980. After 1980 the CIR of active TB was highest in hematologic (219/100,000 population, IRR=26), head and neck (143; 16), lung cancers (83; 9) and was lowest in breast and other solid cancers (38; 4). Conclusions: Individuals living in the US with hematologic, head and neck, and lung cancers had a 9-fold higher rate of developing active TB compared to those without cancer and would benefit from targeted latent TB screening and therapy.
Authors: Matthew P Cheng; Amanda E Kusztos; Tyler D Bold; Vincent T Ho; Brett E Glotzbecker; Candace Hsieh; Meghan A Baker; Lindsey R Baden; Sarah P Hammond; Francisco M Marty Journal: Clin Infect Dis Date: 2019-08-16 Impact factor: 9.079
Authors: Eun Hye Lee; Seung Hyun Yong; Ah Young Leem; Sang Hoon Lee; Song Yee Kim; Kyung Soo Chung; Ji Ye Jung; Moo Suk Park; Young Sam Kim; Joon Chang; Young Ae Kang Journal: Open Forum Infect Dis Date: 2019-04-01 Impact factor: 3.835
Authors: Cesar M Costa; Luiza L Gadotti; Maria C Seiwald; Alessandra C R Salgues; Fernando Ganem; Ellen C T Nascimento; David E Uip; Celso Arrais-Rodrigues; Rodrigo R Munhoz Journal: J Med Case Rep Date: 2021-07-08